Compass Therapeutics, Inc. (CMPX) — Institutional Holders, Q2 2026 (page 3)

216 institutional investment managers reported a CMPX position on SEC Form 13F-HR for the quarter ended June 30, 2026, with a combined reported value of $363.5M. Every filer is listed below, ranked by position value, 100 per page; this page shows ranks 201 to 216. Put and call option positions are excluded, and a firm filing several lots or share classes is shown once with its total.

CMPX 13F holders ranked 201–216 of 216

Institutional investors reporting a position in Compass Therapeutics, Inc. on SEC Form 13F-HR for Q2 2026, ranked by reported value.
InstitutionValueQoQ
ROTHSCHILD INVESTMENT#201 · 765 sh$1.7K+174.2%
Wealth Enhancement Services#202 · 740 sh$1.6KNew
Truvestments Capital#203 · 614 sh$1.3KNew
Optiver Holding B.V.#204 · 568 sh$1.2K-57.5%
PICTON MAHONEY ASSET MANAGEMENT#205 · 467 sh$1.0KNew
GAMMA Investing#206 · 442 sh$968.00+97.3%
NATIONAL BANK OF CANADA#207 · 300 sh$654.00+27.7%
ZIONS BANCORPORATION, NATIONAL ASSOCIATION#208 · 288 sh$631.00New
Marshall & Sterling Wealth Advisors#209 · 200 sh$438.000.0%
SBI Securities , Ltd.#210 · 180 sh$394.00-2.2%
Larson Financial Group#211 · 93 sh$204.00+304.3%
JPL Wealth Management#212 · 89 sh$195.00New
Smartleaf Asset Management#213 · 69 sh$149.000.0%
Steward Partners Investment Advisory#214 · 2 sh$4.00New
Freestone Grove Partners#215 · 1 sh$2.00New
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM#216 · 67,713 sh—-39.7%

Source: Form 13F-HR filings on SEC EDGAR, Q2 2026. Values are as reported by each manager at quarter end. “% of portfolio” is the position’s share of the manager’s total reported 13F value for the same quarter. “New” means the manager filed a 13F for Q1 2026 without this position; a dash means no comparison is available. Where a manager’s own filing is internally inconsistent its value is withheld and it is listed last. 13F data shows reported holdings, not recommendations.